PLRX Pliant Therapeutics, Inc.
Distress ·
Pliant expects to substantially complete the reduction by the end of the second quarter of 2025, with about $3.6 million in severance and related benefits. The cut follows the discontinuation of its BEACON-IPF Phase 2b trial of bexotegrast.
Pliant's board adopted a limited-duration rights plan on March 12, 2025, citing recent accumulations of its common stock. The rights trigger at 10% ownership, or 20% for certain passive investors, and expire on March 11, 2026.
Pliant's board adopted a one-year stockholder rights plan, and the company's trigger is a 10% stake bought without board approval. The release cites unspecified "recent accumulations" of stock and does not name who was buying, less than two weeks after its annual report disclosed the discontinuation of its lead Phase 2b trial.
Pliant Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops integrin-based therapeutics. Its lead program aims at solid tumors by inhibiting integrin-mediated activation of transforming growth factor-beta (TGF-β). Its wholly owned lead candidate, PLN-101095, is an oral small molecule dual selective inhibitor of αvβ8 and αvβ1 integrins for solid tumors that are resistant to immune checkpoint inhibitors. The company describes TGF-β as a potential cause of checkpoint inhibitor resistance and aims to sensitize tumors to checkpoint inhibitors. It announced positive Phase 1 open-label dose-escalation data in March 2025 and December 2025, in which PLN-101095 was given as monotherapy for 14 days followed by pembrolizumab. Across the three highest dose cohorts, there were four responders among 10 secondary ICI refractory patients. The company also maintains a proprietary library of over 15,000 integrin binding molecules for targeted drug delivery.
| Product or program | What it is | Stage |
|---|---|---|
| PLN-101095 | Oral dual inhibitor of αvβ8 and αvβ1 integrins for solid tumors resistant to immune checkpoint inhibitors | Phase 1 open-label dose-escalation data reported in 2025 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development | $109.2 million | $169.3 million |
| Net income (loss) | -$149.3 million | -$210.3 million |
| Cash from operations | -$128.3 million | -$155.5 million |
| Cash and equivalents | $45.4 million | $71.2 million |
| Short-term investments | $145.5 million | $284.5 million |
Pliant Therapeutics, Inc. trades under the ticker PLRX on NASDAQ.
Pliant Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:9PT; LS:A2P4YV.
The SEC Central Index Key (CIK) for Pliant Therapeutics, Inc. is 1746473. Its filings are on SEC EDGAR.
61,921,897 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Pliant Therapeutics, Inc. under United States.
Our directory classifies Pliant Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Pliant Therapeutics, Inc. is US7291391057.
aibio.space lists Pliant Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Pliant Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops integrin-based therapeutics. Its lead program aims at solid tumors by inhibiting integrin-mediated activation of transforming growth factor-beta (TGF-β).
PLN-101095: Oral dual inhibitor of αvβ8 and αvβ1 integrins for solid tumors resistant to immune checkpoint inhibitors Stage: Phase 1 open-label dose-escalation data reported in 2025.
$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Pliant Therapeutics, Inc. reported a net loss of $149.3 million for the fiscal year ended Dec 31, 2025, and used $128.3 million of cash in operations, per its annual report to the SEC.
$109.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
$158.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Reported a financing. SEC Form S-3. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.03,5.03,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio